AI solution to assist in diagnosing respiratory diseases(Korea AI Technology)

  • Problem Statement
    • Chest radiography is one of the most basic and fundamental diagnostic tests used in medicine, accounting for 25% of the annual total numbers of diagnostic imaging procedures. It has been shown that radiologic information changed clinical practice in more than 60% of those who received chest radiography. Unfortunately, miss rates for proper interpretation of chest radiographs go as high as 30% even for experts, leading to increased mortality from treatable diseases. Moreover, the interpretive performance of chest radiographs differ significantly between specialists and non-specialists, up to 30%. Additionally, 10% of chest radiographs are reported to be held back for 30 days until the final report is issued, and only 60% of radiographs are reported by radiologists due to overflowing number of cases to interpret. Improvement in the radiology workflow and efficiency can greatly alleviate the burden.

 

  • Key Value Proposition
    • Prevent difficult cases of chest abnormalities from being missed upon reading chest radiographs.
    • Help physicians make early diagnosis of chest abnormalities in chest radiographs.
    • Increases workflow efficiency in interpretation through decreasing reading time by 34%.

    • Trained to individually detect and locate 10 different radiologic findings

    • The user can customize detectable findings and its visualization method according to user clinical environment

    • Automatically generates case report which includes analysis of each radiologic findings and its location information

    • Provides TB screening AI score to identify tuberculosis on the chest radiograph
  • Training & Validation/ Xây dựng và đánh giá mô hình
    • Trained with a large-scale (>200,000 cases), high-quality (clinically/CT-proven cases) training set.

    • Demonstrated to perform at a standalone accuracy of 97-99% in ROC AUC.19

    • Certified with CE Mark and approved by Korea MFDS.

    • Currently in preparation for regulatory approval in various markets worldwide, including FDA.